VBL Therapeutics Announces Its OVAL Phase 3 Ovarian Cancer Pivotal Study Met The Interim Pre-specified Criterion, Of An Absolute Percentage Advantage Of 10% Or Higher In Ca-125 Response In The Vb-111 Treated Arm Compared To Control